## TAN SAY BENG

Tan Say Beng is Group Director Research at Singapore Health Services (SingHealth) and Senior Associate Dean of the Duke-NUS Graduate Medical School. He also holds or has held faculty appointments at the National University of Singapore's (NUS) Yong Loo Lin School of Medicine, Saw Swee Hock School of Public Health, and the Department of Biostatistics and Bioinformatics at Duke University. He is a board member of the Singapore Clinical Research Institute and also serves on the Science and Technology Advisory Board of the Singapore Sports Institute.

Prior to his current roles, he held various appointments including Executive Director of the National Medical Research Council, Senior Vice President and Chief Scientific Officer of the Singapore Clinical Research Institute, Head of Strategic Planning and Principal Biostatistician at the National Cancer Centre Singapore, Visiting Consultant to the Health Sciences Authority and Director of the Clinical Trials and Epidemiology Research Unit (CTERU), Singapore.

Say Beng received his initial training in Mathematics at Balliol College, University of Oxford, before he proceeded to do a Masters in Applied Statistics there. He then pursued a PhD at Imperial College London in Biostatistics, where he developed Bayesian decision theoretic approaches for the design of clinical trials.

He has more than 70 scientific publications, including first author research articles in leading clinical journals like the BMJ and top research methodology journals like Statistics in Medicine. He has 2 patents to his name, more than 10 research grants as Principal Investigator or Co-Investigator and more than 40 conference abstracts. He has co-authored two books published by Wiley on Sample Sizes for Clinical Studies and Early Phase Clinical Trials, and has also contributed several chapters for other books. He serves on a number of clinical trial steering committees and scientific review panels, has been an invited peer reviewer for many research papers and an Associate Editor of a number of scientific journals, including Statistics in Medicine, Contemporary Clinical Trials and the Journal of Biopharmaceutical Statistics.

## Selected Publications, Books and Book Chapters

- 1. Gandhi M, **Tan SB**, Chung ACY, Machin D (in press). On Developing a Pragmatic Strategy for Clinical Trials: A Case Study of Hepatocellular Carcinoma. *Contemporary Clinical Trials*
- Lim KC, Wang VW, Siddiqui FJ, Shi LM, Chan SYE, Oh HC, Tan SB, Chow PKH (2015). Cost-effectiveness analysis of liver resection versus transplantation for early hepatocellular carcinoma within the Milan criteria. *Hepatology* 61:221: 227-237.
- 3. Chow PKH, Poon DYH, Khin MW, Singh H, Han HS, Goh ASW, Choo SP, Lai HK, Lo RHG, Tay KH, Lim TG, Gandhi M, **Tan SB**, Soo KC for the Asia-Pacific Hepatocellular Carcinoma Trials Group (2014). Multicenter Phase II study of Sequential

Radioembolization-Sorafenib Therapy for inoperable Hepatocellular Carcinoma. *PLOS ONE* 9:e90909.

- 4. Lim SH, Anantharaman V, Sundrum FX, Chan ESY, Ang ES, Yo SL, Jacob E, Goh A, **Tan SB**, Chua T (2013) Stress myocardial perfusion imaging for the evaluation and triage of chest pain in the emergency department: a randomised controlled trial. *Journal of Nuclear Cardiology* 20: 1002-1012.
- 5. Venketasubramanian N, Young S, Tan SS, Chang HM, Umapathi T, Chan B, de Silva A, Wong L, Navarro J, Zhao YD, **Tan SB**, Chen C (2013). Chinese medicine NeuroAiD efficacy stroke recovery extension study (CHIMES-E Study): An observational multicenter study to investigate the longer term efficacy of NeuroAiD in stroke recovery. *Cerebrovascular Disease* 35: 18-22.
- Chung AYF, Ooi LLPJ, Machin D, Tan SB, Goh BKP, Wong JS, Chen YM, Li PCN, Pai N, Thng CH, Yu SWK, Tan BS, Lo RHG, Htoo AMM, Tay KH, Sundram FX, Goh ASW, Chew SP, Liau KH, Chow PKH, Tay KH, Tan YM, Cheow PC, Ho CK, Soo KC (2013). Adjuvant hepatic intra-arterial iodine-131-lipiodol following curative resection of hepatocellular carcinoma: a prospective randomised trial. *World Journal of Surgery* 37: 1356-1361.
- 7. Ahmad A, Lysaght T, Liu JJ, Subramaniam M, **Tan SB**, Capps B (2012). Understanding risk: psychosis and genomics research in Singapore. *Genomics, Society and Policy* 8: 15-28.
- 8. Lim KC, Chow PKH, Allen JC, Siddiqui F, Chan ESY, **Tan SB** (2012). Systematic review of recent outcomes of liver resection for early HCC within Milan criteria. *British Journal of Surgery* 99:1622-1629.
- 9. Xue L, Yen CC, Chang L, Chan HC, Tai BC, **Tan SB**, Duh HBL, Choolani M (2012). An exploratory study of ageing women's perception on access to health informatics via a mobile phone-based intervention. *International Journal of Medical Informatics* 81: 637-648.
- 10. Earnest A, **Tan SB**, Wilder-Smith A, Machin D (2012). Comparing statistical models to predict dengue notifications<sup>-</sup> *Computational and Mathematical Methods in Medicine* 2012: Article ID 758674
- 11. Earnest A, **Tan SB**, Shahidah N, Ong MEH (2012). Geographical variation in ambulance calls in Singapore is associated with socio-economic status. *Academic Emergency Medicine* 19: 180-188
- 12. Yang Y, Goh SY, **Tan SB**, Ho HJ, Emmanuel SC, Ng HS (2012). The burden of diabetes mellitus in elderly patients from an Asian tertiary hospital. *European Journal of Internal Medicine* 23: e1-4.
- 13. Earnest A, **Tan SB**, Wilder-Smith A (2012). Meteorological factors and El Niño Southern Oscillation are independently associated with dengue fever. *Epidemiology and Infection* 140: 1244-1251
- 14. Tan SH, Machin D, **Tan SB** (2012). Sample sizes for estimating differences in proportions can we keep things simple? *Journal of Biopharmaceutical Statistics* 22: 133-140.
- 15. **Tan SB**, Koh GCH, Ding YW, Malhotra R, Ha TC, Pietrobon R, Kusumaratna R, Tie RN, Cunha G, Martins H, Seim A, Altermatt F, Biderman A, Puoane T, Carvalho E, Ostbye T (2011). Inclination towards a research career among first year medical students:

an international study. *South East Asian Journal of Medical Education* 5:49-59.

- 16. Yang Y, Ostbye T, **Tan SB**, Salam ZHA, Ong BC, Yang KS (2011). Risk factors for lower extremity amputation among patients with diabetes in Singapore. *Journal of Diabetes and Its Complications* 25: 382-386
- 17. Chow PKH, Machin D, Chen YM, Zhang X, Khin MW, Hoang HH, Nguyen BD, Jin MY, Lobo R, Findlay M, Lim CH, **Tan SB**, Gandhi M, Soo KC (2011). Randomised Double Blind Trial of Megestrol Acetate versus Placebo in Treatment-Naïve Advanced Hepatocellular Carcinoma. *British Journal of Cancer* 105: 945-952
- Lim KC, Chow PKH, Allen JC, Chia GS, Lim MS, Cheow PC, Chung AYF, Ooi LLP, Tan SB. (2011) Microvascular Invasion is a Better Predictor of Tumour Recurrence and Overall Survival Following Surgical Resection for HCC Compared to the Milan Criteria. Annals of Surgery 254: 108-113
- 19. Julious SA, **Tan SB**, Machin D (2010). *An Introduction to Statistics in Early Phase Clinical Trials*. Wiley-Blackwell, Chichester.
- 20. **Tan SB**, Machin D (2010). Phase II Clinical Trials. In *Pharmaceutical Sciences Encyclopedia: Drug Discovery, Development and Manufacturing.* (Eds: Gad SC, Cavagnaro JA, Nassar AF, Hollenberg PF, Scatina J, Bleavins MR, Carini C, Jurima-Romet M, Rahbari R), DOI: 10.1002/9780470571224.pse211. John Wiley & Sons.
- 21. Wong KS, Chen C, Fu J, Chang HM, Suwanwela NC, Huang Y, Zhao H, Tan KS, Ratanakorn D, Chollate P, Zhao Y, Koh A, Hao Q, Markus HS, CLAIR Study Investigators (2010). Clopidogrel plus aspirin is more effective than aspirin alone in reducing embolisation in patients with acute symptomatic intracranial stenosis the CLAIR Study. Lancet Neurology 9: 489-497.
- 22. Cheung YB, Wee HL, Thumboo J, Goh C, Pietrobon R, Toh HC, Yong YF, **Tan SB**. (2010). Risk communication in clinical trials: A cognitive experiment and a survey. *BMC Medical Informatics and Decision Making* 10:55.
- 23. Wilder-Smith A, Earnest A, **Tan SB**, Ooi EE, Gubler D (2010). Lack of association of dengue activity with haze. *Epidemiology and Infection* 138: 962-967
- 24. Østbye T, Malhotra R, Wong HB, **Tan SB**, Saw SM (2010) The effect of body mass on health-related quality of life among Singaporean adolescents: results from the SCORM study. *Quality of Life Research* 19: 167-176
- 25. Ang MK, **Tan SB**, Lim WT (2010). Phase II clinical trial designs in Oncology: Are we hitting the target? *Expert Review of Anticancer Therapy* 10: 427-438.
- 26. Wong HB, Machin D, **Tan SB**, Wong TY, Saw SM (2010). Ocular component growth curves among Singapore children with different refractive error status. *Investigative Ophthalmology and Visual Science* 51: 1341-1347.
- 27. Wong HB, Machin D, **Tan SB**, Wong TY, Saw SM (2009). Visual impairment and its impact on health-related quality of life in adolescents. *American Journal of Ophthalmology* 147:505-511
- 28. Wong TLT, Khaw PT, Aung T, Foster PJ, Htoon HM, Oen FTS, Gazzard G, Husain R, Devereux JG, Minassian D, **Tan SB**, Chew PTK, Seah SKL (2009) The Singapore 5-Fluorouracil Trabeculectomy Study - Effects on Intraocular Pressure Control and Disease Progression at 3 Years. *Ophthalmology* 116: 175 - 184.
- 29. Venketasubramanian R, Chen CLH, Gan RN, Chan BPL, Chang HM, **Tan SB**, Picard D, Navarro JC, Ratanakorn D, Donnan GA, Bousser MG, on behalf of the CHIMES

Investigators (2009). A Double-Blind, Placebo Controlled, Randomized, Multicenter Study to Investigate CHInese Medicine Neuroaid Efficacy on Stroke recovery. *International Journal of Stroke* 4: 54-60.

- 30. Machin D, Campbell MJ, **Tan SB**, Tan SH (2008). *Sample Size Tables for Clinical Studies*, 3<sup>rd</sup> Edition. Wiley-Blackwell, Chichester.
- 31. **Tan SB**, Wee J, Wong HB, Machin D (2008). Can external and subjective information ever be used to reduce the size of randomized controlled trials? *Contemporary Clinical Trials* 29: 211-219.
- 32. Gao F, **Tan SB**, Machin D, Wong NS (2007). Confirmation of Double-peaked Time Distribution of Mortality for Asian Breast Cancer Patients in a Population-based Study. *Breast Cancer Research* 9: R21
- 33. Leong SS. Toh CK, Lim WT, Lin X, **Tan SB**, Poon D, Tay MH, Foo KF, Ho J, Tan EH (2007). A randomised phase II trial of single agent Gemcitabine, Vinorelbine or Docetaxel in patients with advanced non-small cell lung cancer who have poor performance status and/or are elderly. *Journal of Thoracic Oncology* 2: 230-236
- Machin D, Tan SB (2006) Biometrical aspects of drug development. In Appropriate Dose Selection: How to Optimize Clinical Drug Development (Eds: Venitz J, Sittner W), Springer-Verlag, Berlin; p195-208
- 35. **Tan SB**, Machin D (2006). Phase II trial designs in the presence of stratification. *Statistics in Medicine* 25: 3217-3223.
- 36. Saw SM, Shankar A, **Tan SB**, Taylor H, Tan DTH, Stone RA, Wong TY (2006). A cohort study of incident myopia in Singaporean children. *Investigative Opthalmology and Visual Science* 47: 1839 1844
- 37. Loke YC, **Tan SB**, Cai Y, Machin D (2006). A Bayesian dose finding design for dual endpoint Phase I trials. *Statistics in Medicine*, 25: 3-22.
- 38. Busmanis I, Ho TH, **Tan SB**, Khoo KS (2005). p53 and bcl-2 expression in invasive and pre-invasive uterine papillary serious carcinoma and atrophic endometrium. *Annals Academy of Medicine, Singapore* 34: 421-425
- 39. Tan CS, Tang W, **Tan SB**, Au Eong KG (2005). Visual experience during cataract surgery: a nation-wide survey on the knowledge of optometry students. *Ophthalmic Physiol Opt.* 25:219-23.
- 40. **Tan SB**, Goh C, Thumboo J, Che W, Balram C, Cheung YB (2005). Risk perception is affected by modes of risk presentation among Singaporeans. *Annals Academy of Medicine, Singapore* 34: 184-187.
- 41. Wang YG, Leung DHY, Li M, **Tan SB** (2005). Bayesian designs with frequentist and Bayesian error rate considerations. *Statistical Methods in Medical Research* 14: 445-456.
- 42. Leong SS, Wee J, Tay MH, Toh CK, **Tan SB**, Thng CH, Foo KF, Lim WT, Tan T, Tan EH (2005). Paclitaxel, Carboplatin, and Gemcitabine in metastatic nasopharyngeal carcinoma. A Phase II trial using a triplet combination. *Cancer* 103: 569-575.
- 43. Ashby D, **Tan SB** (2005). Where's the utility in Bayesian data-monitoring in clinical trials. *Clinical Trials* 2:197-208
- 44. Saw SM, **Tan SB**, Fung D, Chia KS, Koh D, Tan DTH, Stone RA (2004). IQ and the association with myopia in children. *Investigative Ophthalmology and Vision Science* 45: 2943-2948.

- 45. Lin K, **Tan SB**, Kolatkar PR, Epstein RJ (2003). Nonrandom intragenic variations in patterns of codon bias implicate a sequential interplay between transitional genetic drift and functional amino acid selection. *Journal of Molecular Evolution* 57: 538 545.
- Cheung YB, Ng GY, Wong LC, Koo WH, Tan EH, Tay MH, Lim D, Poon D, Goh C, Tan SB (2003). Measuring Quality of Life in Chinese Cancer Patients: A New Version of the Functional Living Index - Cancer (Chinese). Annals Academy of Medicine Singapore 32:376-380.
- 47. **Tan SB**, Dear KBG, Bruzzi P, Machin D (2003). Strategy for randomised clinical trials in rare cancers. *British Medical Journal* 327: 47 49.
- 48. **Tan SB**, Dear KBG, Bruzzi P, Machin D (2003). Towards a strategy for randomised clinical trials in rare cancers: an example in childhood S-PNET. *BMJ online*. http://bmj.com/cgi/content/full/327/7405/47/DC1.
- 49. **Tan SB**, Chung YFA, Tai BC, Cheung YB, Machin D (2003). Elicitation of prior distributions for a phase III randomized controlled trial of adjuvant therapy with surgery for hepatocellular carcinoma. *Controlled Clinical Trials* 24: 110 121.
- 50. Teh HS, Ang ES, Wong WC, **Tan SB**, Tan AGS, Chng SM, Lin MBK, Goh JSK (2003). MR renography using a dynamic gradient-echo sequence and low dose gadopentetate dimeglumine as an alternative to radionuclide renography. *American Journal of Roentgenology* 181: 441 450.
- 51. Cheung YB, Khoo KS, Wong ZW, See HT, Toh HC, Epstein RJ, Ng GY, **Tan SB** (2003). Quick-FLIC -- A short questionnaire for assessing quality of life of cancer patients. *Acta Oncologica* 42: 36 – 42.
- 52. **Tan SB**, Machin D (2002). Bayesian two-stage designs for Phase II clinical trials. *Statistics in Medicine* 21: 1991 2012.
- 53. **Tan SB**, Wee SB, Cheung YB (2002). Agreement or prediction: asking and answering the right question. *Annals Academy of Medicine Singapore* 31: 405-407.
- 54. Balram C, Sivathasan C, Cheung YB, **Tan SB**, Tan YS (2002). A limited sampling strategy for the estimation of 12-hour neoral systemic drug exposure in heart transplant recipients. *The Journal of Heart and Lung Transplantation* 21: 1016 1021.
- 55. **Tan SB**, Machin D, Cheung YB, Chung YFA, Tai BC (2002). Following a trial that stopped early: What next for adjuvant hepatic intra-arterial iodine-131-lipiodol in resectable hepatocellular carcinoma? *Journal of Clinical Oncology* 20: 1709.
- 56. **Tan SB**, Machin D, Tai BC, Foo KF, Tan EH (2002). A Bayesian re-assessment of two phase II trials of Gemcitabine in metastatic nasopharyngeal cancer. *British Journal of Cancer* 86: 843-850.
- 57. **Tan SB** (2001). Introduction to Bayesian methods for medical research. *Annals Academy of Medicine Singapore* 30: 444-446.
- 58. **Tan SB**, Smith AFM (1998). Exploratory thoughts on clinical trials with utilities. *Statistics in Medicine* 17: 2771-2791.